S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Regeneron Pharmaceuticals (REGN) Competitors

$981.20
+16.31 (+1.69%)
(As of 02/23/2024 ET)

REGN vs. VRTX, BMY, SNY, ZTS, GSK, PFE, TAK, RPRX, BGNE, and AZN

Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), Sanofi (SNY), Zoetis (ZTS), GSK (GSK), Pfizer (PFE), Takeda Pharmaceutical (TAK), Royalty Pharma (RPRX), BeiGene (BGNE), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.

Regeneron Pharmaceuticals vs.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.

Regeneron Pharmaceuticals currently has a consensus target price of $939.05, indicating a potential downside of 4.30%. Vertex Pharmaceuticals has a consensus target price of $417.27, indicating a potential downside of 2.98%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regeneron Pharmaceuticals
1 Sell rating(s)
5 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.71
Vertex Pharmaceuticals
3 Sell rating(s)
7 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.41

In the previous week, Regeneron Pharmaceuticals and Regeneron Pharmaceuticals both had 34 articles in the media. Vertex Pharmaceuticals' average media sentiment score of 0.60 beat Regeneron Pharmaceuticals' score of 0.52 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Regeneron Pharmaceuticals
9 Very Positive mention(s)
7 Positive mention(s)
17 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Vertex Pharmaceuticals
15 Very Positive mention(s)
4 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

84.2% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 90.8% of Vertex Pharmaceuticals shares are held by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vertex Pharmaceuticals received 58 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.55% of users gave Vertex Pharmaceuticals an outperform vote while only 66.49% of users gave Regeneron Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Regeneron PharmaceuticalsOutperform Votes
1478
66.49%
Underperform Votes
745
33.51%
Vertex PharmaceuticalsOutperform Votes
1536
75.55%
Underperform Votes
497
24.45%

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$13.12B8.21$3.95B$34.7528.24
Vertex Pharmaceuticals$9.87B11.26$3.62B$13.8930.97

Regeneron Pharmaceuticals has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.

Vertex Pharmaceuticals has a net margin of 36.68% compared to Regeneron Pharmaceuticals' net margin of 30.14%. Vertex Pharmaceuticals' return on equity of 21.91% beat Regeneron Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals30.14% 17.61% 13.76%
Vertex Pharmaceuticals 36.68%21.91%16.73%

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 11 of the 17 factors compared between the two stocks.


Get Regeneron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REGN vs. The Competition

MetricRegeneron PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$107.70B$6.67B$5.02B$7.52B
Dividend YieldN/A2.72%2.93%3.86%
P/E Ratio28.2411.1586.2116.27
Price / Sales8.21142.463,059.7555.10
Price / Cash22.0218.1888.8152.42
Price / Book4.154.564.374.63
Net Income$3.95B$155.71M$112.38M$207.21M
7 Day Performance3.50%1.07%0.93%-0.99%
1 Month Performance2.79%10.57%6.93%3.28%
1 Year Performance29.16%1.27%8.82%3.67%

Regeneron Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRTX
Vertex Pharmaceuticals
4.4871 of 5 stars
$426.29
+2.0%
$417.27
-2.1%
+45.0%$109.85B$9.87B30.694,800Analyst Report
Insider Selling
BMY
Bristol-Myers Squibb
4.8327 of 5 stars
$49.45
+1.1%
$61.17
+23.7%
-28.0%$100.61B$45.01B12.8134,300Analyst Downgrade
SNY
Sanofi
3.4694 of 5 stars
$46.39
+1.3%
$57.50
+23.9%
-0.5%$117.35B$46.44B19.6691,573Analyst Upgrade
News Coverage
ZTS
Zoetis
4.8415 of 5 stars
$189.65
+3.0%
$223.78
+18.0%
+18.2%$87.07B$8.08B38.5513,800Analyst Downgrade
GSK
GSK
2.4104 of 5 stars
$41.78
0.0%
N/A+18.0%$85.96B$37.71B13.8869,400Analyst Revision
PFE
Pfizer
4.9992 of 5 stars
$27.51
+1.5%
$36.93
+34.3%
-35.0%$155.33B$58.50B76.4283,000Analyst Report
TAK
Takeda Pharmaceutical
3.2707 of 5 stars
$14.41
-0.9%
$21.33
+48.0%
-7.2%$45.60B$29.81B21.8349,095
RPRX
Royalty Pharma
4.9667 of 5 stars
$30.03
+3.2%
$55.00
+83.2%
-16.5%$17.94B$2.24B96.8751Analyst Report
BGNE
BeiGene
1.4178 of 5 stars
$146.07
+0.1%
$261.40
+79.0%
-32.3%$13.94B$1.42B-15.779,200Upcoming Earnings
AZN
AstraZeneca
3.8839 of 5 stars
$62.84
+1.9%
$80.00
+27.3%
-6.9%$194.82B$45.81B32.7383,500Gap Up

Related Companies and Tools

This page (NASDAQ:REGN) was last updated on 2/23/2024 by MarketBeat.com Staff